1. Home
  2. News Archive

More News

Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...

Glaukos Debuts Epioxa Epi-On Crosslinking at 2026 ASCRS Meeting
Glaukos Debuts Epioxa Epi-On Crosslinking at 2026 ASCRS Meeting

Glaukos launched Epioxa during the 2026 ASCRS meeting in April after announcing the product’s commercial availability in March. The company also shared plans to support access through patient assis...

Cellution Launches OptiCover Amniotic Graft at ASCRS Meeting
Cellution Launches OptiCover Amniotic Graft at ASCRS Meeting

Cellution Biologics launched its OptiCover amniotic graft for ocular use at the 2026 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), which ran April 10-13 in Washington,...

Surgeons Share Experience With Three of Rayner’s Technologies
Surgeons Share Experience With Three of Rayner’s Technologies

Ophthalmologists took a deep dive into describing their experience with two of Rayner’s newest IOLs—the RayOne Galaxy and RayOne EMV Toric—along with the company’s Sophi phaco system at a Rayner-sp...

Emerging Companies Pursuing Ophthalmic Indications, May 2026
Emerging Companies Pursuing Ophthalmic Indications, May 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Pioneering Eye Charities Team Up to Provide Cataract Surgery in Rwanda, Laos, Other Countries
Pioneering Eye Charities Team Up to Provide Cataract Surgery in Rwanda, Laos, Other Countries

Cure Blindness Project and The Fred Hollows Foundation reported April 2 that they are partnering to end avoidable blindness in Rwanda and Laos by 2035. In addition, they will address the cataract s...

Clinical Trial Updates for Ophthalmic Candidates, May 2026
Clinical Trial Updates for Ophthalmic Candidates, May 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

New Tennessee Law Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy
New Tennessee Law Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy

Tennessee has become the 16th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 2076, signed into law by Gov. Bill Lee on April 14,...

Inventors of Luxturna Win $3 Million Breakthrough Prize
Inventors of Luxturna Win $3 Million Breakthrough Prize

Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...

Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells

Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...

Weekly Poll of MDs, US and Western Europe, May 2026
Weekly Poll of MDs, US and Western Europe, May 2026

May 2026 Ophthalmic News Briefs
May 2026 Ophthalmic News Briefs

Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...

Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion
Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion

German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...

Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane
Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane

Alcon reported May 6 that its Q1-2026 net sales were $2.69 billion, a 10 percent increase (+6 percent cc) over $2.45 billion in Q1-2025. Surgical net sales totaled $1.46 billion, consisting of $438...

Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...

Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar
Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar

Sweden’s Xbrane Biopharma announced April 30 that it had resubmitted the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA. A complete response letter from...

Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate
Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate

South Korea’s Novelty Nobility announced May 4 that it had expanded its manufacturing agreement with AGC Biologics to advance retinal disease candidate NN4101 through process development and GMP ma...

Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate
Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate

Kubota Vision and Laboratoires Kôl announced May 4 that they had signed a supply and licensing agreement to bring emixustat hydrochloride, an oral treatment candidate for Stargardt disease, to pati...

US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program
US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program

Opus Genetics announced May 4 that the US FDA had accepted OPGx-LCA5, a gene therapy candidate targeting Leber congenital amaurosis type 5, into the new Rare Disease Evidence Principles (RDEP) prog...

BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Announces Full CE Marking for its Virtuoso Platforms

BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...

Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird

Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...

Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells

Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...

Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million

Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...

Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt

Belite Bio announced April 21 that it had initiated a rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califor...

US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain

Israel’s PRF Technologies and its majority-owned subsidiary LayerBio reported on April 28 that the US FDA had signed off on their investigational new drug (IND) application, allowing LayerBio to pr...

Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease

Taiwan’s Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have teamed up to address unmet needs in corneal and ocular surface disease, Formosa announced April 30. The partner...

EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate
EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate

Ray Therapeutics announced April 29 that the European Medicines Agency had granted Priority Medicines (PRIME) designation to RTx-015, its optogenetic therapy candidate for retinitis pigmentosa (RP)...

New Law in Tennessee Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy
New Law in Tennessee Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy

Tennessee has become the 16th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 2076, signed into law by Gov. Bill Lee on April 14,...

Inventors of Luxturna Win $3 Million Breakthrough Prize
Inventors of Luxturna Win $3 Million Breakthrough Prize

Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...

Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion
Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion

Swiss company Roche reported April 23 that Vabysmo sales in Q1-2026 were CHF 1.024 billion ($1.3 billion, calculated for March 31, 2026), up 13 percent in constant currency from CHF 1.018 billion i...

New OD Survey Looks at Factors Shaping Premium IOL Education Before Referral
New OD Survey Looks at Factors Shaping Premium IOL Education Before Referral

Optometrists play an increasingly important role in educating patients about cataract surgery prior to referral, as those patients’ expectations continue to rise. Key findings from Market Scope’s i...

US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026

The US Centers for Medicare and Medicaid Services (CMS) issued J-codes in Q1-2026 for Harrow’s Iopidine and Glaukos’ Epioxa and Epioxa HD. In addition, the CMS issued Q-codes for Zydec’s interchang...

Revenio Group to Acquire Visionix in $341 Million Deal
Revenio Group to Acquire Visionix in $341 Million Deal

Finland’s Revenio Group, parent of ophthalmic diagnostic company iCare, announced April 13 that it would acquire France-based Visionix in a deal worth €290 million ($341 million). Revenio said that...

US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO
US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO

Genentech announced April 9 that the US FDA had approved the extension of dosing intervals for Vabysmo (faricimab-svoa) beyond six months for patients with macular edema due to retinal vein occlusi...

Lenz Submits Marketing Application for Vizz Presbyopia Drop in the UK
Lenz Submits Marketing Application for Vizz Presbyopia Drop in the UK

Lenz Therapeutics announced April 20 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for Vizz, an eye drop targeting pres...

Santen to Market Five of AbbVie’s Glaucoma Drops in China
Santen to Market Five of AbbVie’s Glaucoma Drops in China

Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...

Theialife Names Ruggia as President, CEO, Readies Phase III Oral Myopia Candidate
Theialife Names Ruggia as President, CEO, Readies Phase III Oral Myopia Candidate

Theialife, of Dover, Delaware, announced April 23 that it had appointed Thomas Ruggia as president and chief executive officer. Theialife co-founder Sundeep Aurora will continue to oversee scientif...

Cencora Expands Reach in Retina Care with Acquisition of EyeSouth Partners
Cencora Expands Reach in Retina Care with Acquisition of EyeSouth Partners

Cencora’s agreement to purchase the retinal business of EyeSouth Partners for $1.1 billion is the company’s second major acquisition in an aggressive campaign to become a major, vertically integrat...

EU Softens Stance on MDR Transition to Ensure Availability of Needed Devices
EU Softens Stance on MDR Transition to Ensure Availability of Needed Devices

Implementation of the European Union’s Medical Device Regulation (MDR) has proven more complex and prolonged than originally anticipated. The new standards took effect in May 2021, ending a four-ye...

Nanodropper Bottle Tip Adaptor Goes from Simple Idea to Global Product
Nanodropper Bottle Tip Adaptor Goes from Simple Idea to Global Product

Mu Medical has been turning heads for years with claims that its Nanodropper bottle tip adaptor cuts typical eye drop volume more than 60 percent, resulting in a single medicine bottle lasting seve...

Fundraising Slows in Q1-2026 for Ophthalmic Firms
Fundraising Slows in Q1-2026 for Ophthalmic Firms

Market Scope identified 17 ophthalmic deals in Q1-2026, down from 21 in Q1-2025. Fundraising totals reached $856.6 million, a decline from $930.2 million in Q1-2025. The number of deals was below t...

Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth
Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth

Biogen reported March 31 that it had agreed to acquire Apellis Pharmaceuticals, maker of Syfovre, for about $5.6 billion in cash to expand its portfolio of rare-disease medicines. Under the deal, e...

Halma Acquires Surgistar to Augment MST’s Ophthalmic Instrument Portfolio
Halma Acquires Surgistar to Augment MST’s Ophthalmic Instrument Portfolio

UK-based Halma, the parent of ophthalmic instrument maker MicroSurgical Technology (MST) announced April 13 that it had acquired Surgistar, of Vista, California, as an add-on to MST. No financial d...

Select US FDA Approvals and Clearances in March 2026
Select US FDA Approvals and Clearances in March 2026

The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in March 2026, according to the agency’s database. Oculus received clearance for its Pentacam Cor...

PDUFA Dates for Ophthalmic Drug Candidates, April 2026
PDUFA Dates for Ophthalmic Drug Candidates, April 2026

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

Incremental Improvements are the Trend in Vitrectomy Systems
Incremental Improvements are the Trend in Vitrectomy Systems

New retinal surgical device offerings from manufacturers feature innovative fluidics systems and stiffer small-gauge instruments. Manufacturers hope the improvements they bring to vitrectomy surger...

Bausch + Lomb Launches Preloaded enVista Envy Trifocal IOL in Europe
Bausch + Lomb Launches Preloaded enVista Envy Trifocal IOL in Europe

Bausch + Lomb announced April 7 the commercial availability in Europe of the enVista Envy trifocal intraocular lens (IOL), preloaded in the EyeGility lens delivery system. Luc Bonnefoy, president o...

New Hampshire Governor Vetoes Bill to Allow ODs to Perform SLT, LPI, YAG Capsulotomy
New Hampshire Governor Vetoes Bill to Allow ODs to Perform SLT, LPI, YAG Capsulotomy

New Hampshire Gov. Kelly Ayotte on March 27 vetoed House Bill 349, which would have expanded the scope of practice for optometrists in the state, allowing them to perform selective laser trabeculop...

First Human Cataract Surgery Performed with ForSight’s Robotic Aid
First Human Cataract Surgery Performed with ForSight’s Robotic Aid

Israel’s ForSight Robotics announced April 7 that the first cataract surgery in a human patient had been performed with its Jasper robot-assisted surgical platform. The procedure was performed on a...

J&J Continues to Reduce JLABS Footprint with Exit from New York
J&J Continues to Reduce JLABS Footprint with Exit from New York

Johnson & Johnson is stepping away from its JLABS incubator site in New York, reducing its JLABS locations in the US to those in San Diego, San Francisco, and Boston. The New York site opened in 20...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more